Alzheimer's Disease: Lessons Learned from Amyloidocentric Clinical Trials (Q35695716)

9 August 2017

1 reference

title

Alzheimer's Disease: Lessons Learned from Amyloidocentric Clinical Trials (English)

1 reference

9 August 2017

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26187557%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Anastasia Tjan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26187557%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

author name string

Thomas Eko Purwata

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26187557%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

publication date

18 July 2015

1 reference

9 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26187557%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26187557%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26187557%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

page(s)

487-502

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26187557%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40263-015-0257-8

14 June 2020

exact match

0 references

cites work

Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Alzheimer disease therapy--moving from amyloid-β to tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Functional network disruption in the degenerative dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

A population-based clinicopathological study in the oldest-old: the 90+ study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Neurodegenerative tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Tau-mediated neurodegeneration in Alzheimer's disease and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Memantine in the treatment of mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Decreased clearance of CNS beta-amyloid in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Total and phosphorylated tau protein as biological markers of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

[18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Revising the definition of Alzheimer's disease: a new lexicon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Identification of beta-secretase (BACE1) substrates using quantitative proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Bace1 modulates myelination in the central and peripheral nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Control of peripheral nerve myelination by the beta-secretase BACE1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Lessons from a BACE1 inhibitor trial: off-site but not off base.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Evidence supporting a role for anti-Abeta antibodies in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

The mechanism of γ-Secretase dysfunction in familial Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Angiogenesis: a team effort coordinated by notch.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Pharmacodynamics of selective inhibition of γ-secretase by avagacestat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

A novel pathway for amyloid precursor protein processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

The therapeutics of Alzheimer's disease: where we stand and where we are heading

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Immunological and anti-chaperone therapeutic approaches for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Abeta species removal after abeta42 immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Immunotherapy for Alzheimer's disease: DNA- and protein-based epitope vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Lessons from the AN 1792 Alzheimer vaccine: lest we forget.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Amyloid-beta immunisation for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Active immunotherapy options for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

A single ascending dose study of bapineuzumab in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Solanezumab for the treatment of mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Vascular risk factors for Alzheimer's disease: an epidemiologic perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0257-8

15-year longitudinal study of blood pressure and dementia

21 January 2018

1 reference

12 December 2020

Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors

1 reference

12 December 2020

Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse

1 reference

12 December 2020

A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects

1 reference

12 December 2020

Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men

1 reference

12 December 2020

Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β

1 reference

12 December 2020

10.1007/S40263-015-0257-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26187557%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

1 reference